Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 800 participants.
Also called NCT02831205
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 800 participants
- Registry
-
NCT02831205
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Terminated
Technical summary
Registry record NCT02831205. Randomized; no masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2017-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
- Acronym
- ABSORB-LONG
- Condition
- Percutaneous Transluminal Coronary Angioplasty
- Intervention (Device)
- everolimus-eluting bioresorbable vascular (Absorb) scaffold
- Intervention (Device)
- everolimus-eluting cobalt-chromium (Xience) stent
- Lead sponsor
- Duk-Woo Park, MD
- Collaborator
- CardioVascular Research Foundation, Korea
Record details
- Record id
cardio:ct-nct02831205- Content hash
d0027144fb1e75534faeb489392bd0bdb6f2dacf9c17fb4d166e2aa001982472